COYA vs. NMRA, ORGO, AURA, KALV, ETON, PRME, VALN, KRRO, ENGN, and GLUE
Should you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Neumora Therapeutics (NMRA), Organogenesis (ORGO), Aura Biosciences (AURA), KalVista Pharmaceuticals (KALV), Eton Pharmaceuticals (ETON), Prime Medicine (PRME), Valneva (VALN), Korro Bio (KRRO), enGene (ENGN), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry.
Coya Therapeutics vs.
Coya Therapeutics (NASDAQ:COYA) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.
In the previous week, Neumora Therapeutics had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 4 mentions for Neumora Therapeutics and 1 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 1.95 beat Neumora Therapeutics' score of 0.06 indicating that Coya Therapeutics is being referred to more favorably in the media.
39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 9.8% of Coya Therapeutics shares are held by company insiders. Comparatively, 26.4% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Coya Therapeutics currently has a consensus target price of $16.25, indicating a potential upside of 202.04%. Neumora Therapeutics has a consensus target price of $16.50, indicating a potential upside of 704.88%. Given Neumora Therapeutics' higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Coya Therapeutics.
Coya Therapeutics' return on equity of -31.63% beat Neumora Therapeutics' return on equity.
Coya Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.71, meaning that its share price is 171% more volatile than the S&P 500.
Coya Therapeutics has higher revenue and earnings than Neumora Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.
Neumora Therapeutics received 9 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 94.12% of users gave Coya Therapeutics an outperform vote while only 89.29% of users gave Neumora Therapeutics an outperform vote.
Summary
Coya Therapeutics beats Neumora Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Coya Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coya Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:COYA) was last updated on 1/21/2025 by MarketBeat.com Staff
